title: TNF-alpha enhanced allergic sensitization to house dust mite in brown Norway rats.
abstract: We have recently demonstrated that pulmonary exposure to residual oil fly ash (ROFA) resulted in enhanced sensitization to house dust mite (HDM) and augmented the development of allergic lung disease after allergen challenge. This effect was associated with increased tumor necrosis factor alpha (TNF-alpha), a macrophage- and epithelial cell-derived cytokine that promotes granulocyte migration to the lung. The present study examined whether exogenous administration of TNF-alpha enhances sensitization to HDM. One day prior to pulmonary sensitization with 10 microg HDM (5 microg each on days 1 and 3), female Brown Norway rats were instilled via the trachea with either 2.0 microg recombinant rat TNF-alpha, 2.0 microg bovine serum albumin (BSA), or 1,000 microg ROFA, and were challenged with 10 microg HDM 14 days later. Antigen-induced immediate bronchoconstriction responses, antigen-specific immunoglobulin E (IgE) titers, lymphocyte proliferation, (cytokines (TNF-alpha and interleukin [IL]-13), and eosinophils were elevated in rats treated with ROFA or TNF-alpha compared with BSA-treated controls after HDM challenge. Intratracheal administration of anti-TNF-alpha monoclonal antibody during ROFA exposure did not reduce ROFA-enhanced lymphocyte proliferation or IgE titers, but had a trend for reduced pulmonary inflammation. This study demonstrates that TNF-alpha has similar adjuvant activity as ROFA, but other factors may fulfill this function when TNF-alpha activity is blocked.
authors.affiliation: University of North Carolina at Chapel Hill, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Lambert
authors.forename: M K
authors.initials: MK
authors.lastname: Selgrade
authors.forename: D W
authors.initials: DW
authors.lastname: Winsett
authors.forename: M I
authors.initials: MI
authors.lastname: Gilmour
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D039741:Antigens, Dermatophagoides; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016084:Bronchoconstriction / Q000187:drug effects; D002244:Carbon / Q000009:adverse effects / Q000276:immunology; D060729:Coal Ash; D016207:Cytokines / Q000032:analysis / Q000235:genetics; D004195:Disease Models, Animal; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007073:Immunoglobulin E / Q000096:biosynthesis; D007442:Intubation, Intratracheal; D008213:Lymphocyte Activation / Q000187:drug effects; D008925:Mites / Q000276:immunology*; D052638:Particulate Matter; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011914:Rats, Inbred BN; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D039741:Antigens, Dermatophagoides; D060729:Coal Ash; D016207:Cytokines; D006023:Glycoproteins; D052638:Particulate Matter; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E; D002244:Carbon